TGF- α and IL-6 plasma levels selectively identify CML patients that fail to achieve an early molecular response or progress in the first year of therapy.
Abstract
Early molecular response (EMR, BCR-ABL1 (IS)⩽10% at 3 months) is a strong predictor of outcome in imatinib-treated chronic phase chronic myeloid leukemia (CP-CML) patients, but for patients who transform early, 3 months may be too late for effective therapeutic intervention.
http://www.ncbi.nlm....pubmed/26898188
TGF- α and IL-6 plasma levels selectively identify CML patients that fail to achieve an early molecular response or progress in the first year of ther
Started by
gerry
, Feb 24 2016 07:21 PM
No replies to this topic
1 user(s) are reading this topic
0 members, 1 guests, 0 anonymous users
